** Shares of drugmaker Viatris fall 2.2% to $12
** The U.S FDA declined to approve VTRS and partner Mapi Pharma's injection for treating multiple sclerosis $(MS)$
** The companies are reviewing the contents of the health regulator's complete response letter and will soon determine the appropriate next steps, they said
** VTRS and Mapi were seeking the FDA's nod for GA Depot, a long-acting version of glatiramer acetate
** Glatiramer acetate is approved under the brand name Copaxone, manufactured by Teva Pharmaceutical Industries
** MS is a disease where the immune system attacks brain cells, causing motor disabilities
** The receipt of the FDA's letter will not impact VTRS's 2024 forecast or its new product revenue range of $450 million to $550 million - VTRS
** Including session moves, stock has risen 19.5% in the last 12 months
(Reporting by Sneha S K in Bengaluru)
((Sneha.SK@thomsonreuters.com;))
Comments